Trisalus Life Sciences Inc (TLSI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -39,227 | -30,045 | -59,363 | -47,187 | 4,767 |
| Depreciation Amortization | 1,675 | 1,356 | 684 | 398 | N/A |
| Accounts receivable | -1,634 | -1,719 | -1,979 | -200 | N/A |
| Other Working Capital | 2,497 | -9,285 | 739 | 2,300 | 1,303 |
| Other Operating Activity | 18,677 | -1,150 | 9,341 | 12,376 | -7,808 |
| Operating Cash Flow | $-18,012 | $-40,843 | $-50,578 | $-32,313 | $-1,738 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -838 | -345 | -588 | -655 | N/A |
| Purchase Sale Intangibles | N/A | N/A | N/A | -131 | N/A |
| Other Investing Activity | 0 | 0 | -1,000 | -1,131 | 60 |
| Investing Cash Flow | $-838 | $-345 | $-1,588 | $-1,786 | $60 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 10,000 | 25,000 | 0 | N/A | 544 |
| Debt Repayment | -81 | -84 | -87 | -131 | N/A |
| Common Stock Issued | 22,914 | 15,613 | 179 | 94 | N/A |
| Other Financing Activity | -2,069 | -2,593 | 54,537 | 13,499 | 0 |
| Financing Cash Flow | $30,764 | $37,936 | $54,629 | $13,462 | $544 |
| Beginning Cash Position | 8,875 | 12,127 | 9,664 | 30,301 | 1,335 |
| End Cash Position | 20,789 | 8,875 | 12,127 | 9,664 | 201 |
| Net Cash Flow | $11,914 | $-3,252 | $2,463 | $-20,637 | $-1,134 |
| Free Cash Flow | |||||
| Operating Cash Flow | -18,012 | -40,843 | -50,578 | -32,313 | -1,738 |
| Capital Expenditure | -918 | -345 | -588 | -655 | N/A |
| Free Cash Flow | -18,930 | -41,188 | -51,166 | -32,968 | -1,738 |